MRHFM Hopeful for Silica Microparticle as Promising Treatment for Malignant Mesothelioma

A promising study was recently published reporting that targeted chemotherapy delivers cancer-fighting drugs directly into mesothelioma cells, while leaving healthy cells intact.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
MRHFM Mesothelioma Law Firm
It cannot stop here, however, this research needs to fuel more studies and funding toward the cause.

St. Louis, Missouri (PRWEB) February 18, 2014

While mesothelioma cancer research is underway and making strides every day, there is still no cure for mesothelioma. MRHFM is hopeful that a new study published by the University of Vermont will add to the ongoing progression of research for malignant mesothelioma cancer.

The study, titled "Microspheres targeted with a mesothelin antibody and loaded with doxorubicin reduce tumor volume of human mesothelioma xenografts," published in BMC Cancer on the BioMedCentral website in September 2013, discusses first-line treatments such as systematic chemotherapy, which researchers say have limited effectiveness and serious side effects such as attacking both healthy cells and cancer cells. Data suggested that targeted therapy results in greater chemotherapeutic efficacy with fewer adverse side effects than the administration of doxorubicin (DOX) alone. Targeted microparticles are an attractive option for localized drug delivery.

“This study along with many others that are specific to malignant mesothelioma are the pieces that will come together and bring a cure,” said Neil Maune, partner at MRHFM. “It cannot stop here, however, this research needs to fuel more studies and funding toward the cause. We strive to continuously provide the most up to date information regarding new studies, treatments and breakthroughs on our website http://www.mesotheliomabook.com. The law firm of MRHFM will continue to be an advocate for our clients and their families who are suffering from mesothelioma cancer.”

Malignant mesothelioma(s) are cancerous tumors of the lining of the pleura (lung and chest cavity), caused exclusively by asbestos exposure. Many believed that only long-term exposure to asbestos caused malignant mesothelioma, but it is now known that even short-term and second-hand exposure to asbestos dust can cause this aggressive and debilitating disease.

If you or someone you know has been diagnosed with mesothelioma or are experiencing symptoms of mesothelioma, contact a doctor immediately to get tested. MRHFM is the largest firm exclusively devoted to helping mesothelioma victims and their families. Speak directly with an attorney at MRHFM today by calling 866-373-5000 or visit http://www.mesotheliomabook.com.

About Maune Raichle Hartley French & Mudd, LLC
Maune Raichle Hartley French & Mudd, LLC is a mesothelioma law firm based in St. Louis, MO. With offices across the country, their size and exclusive focus on mesothelioma cases allows them to represent clients through the process as quickly as possible and maximize their clients’ recovery. The attorneys at MRHFM have represented thousands of victims exposed to asbestos. The firm has 29 attorneys across the country, 16 investigators, 7 client service managers, and additional support staff including paralegals and legal assistants. For more information about Maune Raichle Hartley French & Mudd, LLC, visit http://www.mesotheliomabook.com.

###


Contact